In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data.
The abstract entitled ‘Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)‘ Abstract 1357O, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What did the PROpel study teach us about the efficacy and safety of combined abiraterone and olaparib as first-line therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? (0:11)
- What did the updated results show in terms of overall survival? (1:18)
- What did the subgroups analysis show with regard to the impact of biomarkers? (2:15)
- How clinically meaningful are outcomes with combined abiraterone and olaparib? (3:39)
- Where do you see this approach sitting in the treatment paradigm for mCRPC? (4:16)
Disclosures: Fred Saad is a consultant for AstraZeneca; receives grant/research support from AstraZeneca; is on the advisory board for AstraZeneca; and receives honoraria/honorarium from AstraZeneca.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
